Search

This study defines the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QOL) questionnaire designed to measure the QOL of patients with ovarian cancer. The ovarian cancer module (EORTC QLQ-OV28) was developed to supplement the EORTC QLQ-C30. The core questionnaire and the QLQ-OV28 were prospectively administered to 368 ovarian cancer patients after they had been treated with radical or debulking surgery followed by chemotherapy. The QLQ-OV28 module assesses abdominal/gastrointestinal symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal/menopausal symptoms, body image, attitude to disease/treatment and sexual functioning. Questionnaires were well accepted by patients, baseline compliance rates were 86%, 72% provided a second assessment, less than 3% of the items had missing data. Multi-trait scaling analyses confirmed the hypothesised scales. All hypothesised scales exhibited good psychometric properties. These results support the clinical and psychometric validity of the EORTC QLQ-OV28 module as a supplement to the EORTC QLQ-C30. [Copyright &y& Elsevier]

The objective was to understand treatment patterns and persistence, and associated costs among type 2 diabetes (T2DM) patients starting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in routine clinical practice in Spain. T2DM patients >=18 years initiating a new treatment with the most widely used GLP-1 RAs, either once-weekly exenatide-QW, once-weekly dulaglutide, or once-daily liraglutide (index therapy) between 01/11/2015 and 30/06/2017 (index date) were included. The proportion of patients persistent at one year was highest among dulaglutide patients and lowest among exenatide-QW patients. [Extracted from the article]